CP	carboplatin/paclitaxel
OC	ovarian cancer
IB	ixabepilone ± bevacizumab
WES	whole exome sequencing
CR/PR	complete/partial response
SD/PD	stable/progressive disease
PFS	progression-free survival
HGSOC	high-grade serous ovarian cancer
CNV	copy number variant
LOH	loss of heterozygosity
PFI	platinum-free interval
OS	overall survival